Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Oral Sessions Acute Lymphoblastic Leukemia ALL - Therapy, excluding Transplantation

614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy

Watch Session

159 Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)  according to ASH clinically relevant abstract
 
160 ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies according to ASH clinically relevant abstract

Claire Roddie, PhD, MD1*, Maeve A O'Reilly, MBBCHBAO2, Maria A V Marzolini, et al.

 

161 Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients according to ASH clinically relevant abstract

Xian Zhang, Junfang Yang, Wenqian Li, et al.

 

162 CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia according to ASH clinically relevant abstract

Rui Zhang, Juan Xiao, Zhouyang Liu, et al.

 

163 Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) according to ASH clinically relevant abstract

Nitin Jain, Gail J. Roboz, Marina Konopleva, et al.

 

164 A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study according to ASH clinically relevant abstract

Erica Brivio, Franco Locatelli, Adriana Thano, et al.